ARA-290 (Cibinetide)

Tissue repairInvestigational (Phase 2)

Also known as: Erythropoietin-derived peptide

A peptide based on EPO that protects nerves without raising red blood cells.

Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.

How it works

Activates the innate repair receptor (EPO receptor plus CD131), calming inflammation and supporting small-nerve regrowth.

Evidence by goal

GoalGradeWhat the grade means
Nerve pain & neuropathyBHuman trials (smaller, mixed, or approved outside the US)
Blood sugar & metabolicCLimited human data, case series or practitioner reports

At a glance

Route
Subcutaneous daily
Half-life
Minutes; effects last weeks

Reported dosing

4 mg SC daily for 28 days (trial dose).

Timing: Once daily.

Cycle: 28-day course.

From approved labels where they exist, otherwise from published trials and practitioner reports.

Side effects

  • Injection-site reactions
  • Generally well tolerated

Who should avoid it

  • Pregnancy

Often combined with

Alone.

Key findings

Phase 2 trials in sarcoidosis and type 2 diabetes improved small-fiber nerve density and neuropathic pain.

Where it is legal (Oct 2026)

USNot approved
CanadaNot approved
MexicoNot approved
EUNot approved

Sources

Open ARA-290 (Cibinetide) in the Peptide Guide Compare all peptides by goal

Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.

Natoorales and e4life.io (Mexico residency and immigration help) are sister businesses founded by Ian Kain.

Scroll to Top